Gemcitabine Fiction Compared To The Authentic Information And Facts

Atrial fibrillation/flutter (AF) was the main indication for digoxin therapy in our HF http://www.selleckchem.com/products/birinapant-tl32711.html cohort, almost 60% of the patients on digoxin had AF. Our propensity score-matching reduced the absolute standardised differences for all observed covariates less than 5%, demonstrating substantial improvement in covariate balance across the groups. During a median follow up of 46.1?��?11.2?months, 1872 patients (65.9%) died, and 2203 (77.6%) were hospitalised for worsening heart failure. The patients with HF who received digoxin presented a survival significantly higher than that of the patients not taking this treatment (HR of death [CI 95%]: 0.90 [0.84 to 0.97]), not only in men (HR of death: 0.77 [0.72 to 0.82]), but also in women (HR of death: 0.93 [0.88 to 0.98]), as well as in patients with non-systolic HF (HR of death: 0.86 [0.79 to 0.92]), and those with systolic HF (HR of death: 0.92 [0.89 to 0.95]), (p? http://www.selleck.cn/products/azd9291.html on the survival of patients with HF was mainly caused by a reduction of the cardiovascular mortality (HR of death: 0.87 [0.83 to 0.91]) (p? http://www.selleckchem.com/products/Gemcitabine-Hydrochloride(Gemzar).html digoxin (7.4) in comparison with those not receiving digoxin (8.6), both for the patients with HF-PSF (digoxin therapy: 7.1 vs. non-digoxin therapy: 8.0), and for the patients with HF-DSF (digoxin therapy: 7.9 vs. non-digoxin therapy: 9.3) (p?